RARE
Ultragenyx Sets Sights on a Strong Year of Value Creation in 2025
The biotechnology company, Ultragenyx, has reported a successful fourth quarter and full year 2024 financial results conference call, highlighting its progress in advancing late-stage programs for serious genetic conditions. The company's CEO and President, Emil Kakkis, emphasized that 2024 was a pivotal year for the company, with significant